Sign inJoin waitlistJoin the waitlist

Andrew Rezvani

Clinical Chief, Stanford University, Division of Blood & Marrow Transplantation · Stanford Health Care

Credentials: · · ·

History

Stanford University Division · Stanford Health Care
Present
Stanford Health Care
Present
Stanford Health Care
Present

Medical Oncology
2004–2006
Internal Medicine
Duke University Hospital
2001–2004
Temple University School of Medicine
1997–2001

Research

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis
New England Journal of Medicine · 2023 · 550 citations
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Nature Medicine · 2021 · 534 citations
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
Blood · 2017 · 256 citations

David Miklos
34 papers
Sally Arai
33 papers
Lori Muffly
32 papers
Robert Lowsky
32 papers
Laura Johnston
31 papers
Robert Negrin
31 papers
Wen-Kai Weng
31 papers
Judith Shizuru
30 papers
Everett Meyer
29 papers
Matthew Frank
25 papers · 2 as a fellow
Parveen Shiraz
25 papers
Surbhi Sidana
23 papers

Clinical trials

Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
Principal investigator · Completed · Phase 2
Andrew Rezvani
2017–2021
Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
Principal investigator · Completed · Phase 1
Stanford University
2016–2017
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Principal investigator · Completed
Fred Hutchinson Cancer Center
2006–2013
Nutrition OUtReach In Systems of Healthcare
Site PI · Recruiting
University of Kansas Medical Center
2025–2029